Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Raelynn Paris

Nurse Practitioner, Family Weirton, WV Nurse Practitioner

NPI 1790227262 CMS profile 10554741

651 Colliers Way, Weirton, WV 26062

Open in the dashboard

General payments

$5,883

188 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Raelynn Paris of Weirton, WV is reported in the CMS Open Payments database as having received $5,883 across 188 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $117 1
2023 General $1,220 46
2022 General $3,262 91
2021 General $1,284 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raelynn Paris
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Raelynn Paris were reported at $117. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Raelynn Paris Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,284 $124 $35–$379 $132
2022 $3,262 $141 $44–$430 $149
2023 $1,220 $154 $49–$476 $160
2024 $0 $165 $51–$504 $164
2025 $117 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. LivaNova USA, Inc. $1,163 10 payments
  2. Biohaven Pharmaceutical Holding Company Ltd. $786 30 payments
  3. Biohaven Pharmaceuticals, Inc. $770 30 payments
  4. UCB, Inc. $755 29 payments
  5. Biogen, Inc. $457 10 payments
  6. EMD Serono, Inc. $338 15 payments
  7. Alexion Pharmaceuticals, Inc. $330 10 payments
  8. Lilly USA, LLC $217 10 payments
  9. Sumitomo Pharma America, Inc. $182 9 payments
  10. Kyowa Kirin, Inc. $147 8 payments
  11. Other $738 27 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,142 184 payments
  2. Travel and Lodging $650 1 payment
  3. Education $91 3 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT $1,556 60 payments
  2. VNS Therapy $959 2 payments
  3. Briviact $666 24 payments
  4. VUMERITY $427 9 payments
  5. ULTOMIRIS $330 10 payments
  6. EMGALITY $217 10 payments
  7. REYVOW $217 10 payments
  8. APTIOM $216 12 payments
  9. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $179 7 payments
  10. MAVENCLAD $159 11 payments
  11. Other $1,161 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record